Drugs Archives - Page 18 of 66 - ��ýҕ�l Health News

KHN’s ‘What the Health?’: Congress Races the Clock

Sen. Raphael Warnock’s re-election in Georgia will give Democrats a clear-cut Senate majority for the first time in nearly a decade. Meanwhile, the current Congress has only days left to tackle major unfinished business on the health agenda, including fending off scheduled pay cuts for doctors and other health providers in the Medicare program. Joanne Kenen of the Johns Hopkins Bloomberg School of Public Health and Politico, Anna Edney of Bloomberg News, and Sandhya Raman of CQ Roll Call join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Dec. 8, 2022

A photo shows a hand holding a box containing Paxlovid pills.

COVID-19

Paxlovid Has Been Free So Far. Next Year, Sticker Shock Awaits.

The government soon will stop paying for the covid drug that has proved to be the most effective at keeping patients alive and out of the hospital.

By Hannah Recht

Dec. 7, 2022

Various pills of different colors and shapes cover a 100 dollar bill. In the center, the face of Benjamin Franklin is visible.

Employers Use Patient Assistance Programs to Offset Their Own Costs

Some insurers and employers are tapping into assistance programs meant for individual patients. The concern: Some costly drugs could be harder for patients to access.

By Julie Appleby

Dec. 6, 2022

KHN On Air

Journalists Discuss Medicaid Rules, Opioid Settlement Funds, and the Public Health Workforce

KHN and California Healthline staff made the rounds on national and local media this week to discuss their stories. Here’s a collection of their appearances.

Dec. 3, 2022

A photo shows petri dishes arranged in a row over scans of DNA and RNA.

Patients for Profit: How Private Equity Hijacked Health Care

The Business of Clinical Trials Is Booming. Private Equity Has Taken Notice.

Private equity-backed Headlands Research heralded its covid-19 vaccine trials as a chance to boost participation among diverse populations, then it shuttered multiple sites that conducted them.

By Rachana Pradhan

Dec. 2, 2022

Watch: The Politics of Health Care in California

KHN senior correspondent Angela Hart discussed the most pressing health care issues in California with the nonpartisan group Democracy Winters in mid-November, touching on a variety of issues, from the state’s effort to transform its Medicaid program to its plan to produce generic insulin.

Dec. 2, 2022

Podcast

KHN’s ‘What the Health?’: Medicaid Machinations

The lame-duck Congress has returned to Washington with a long health care to-do list and only a little time. Meanwhile, some of the states that have not yet expanded Medicaid eligibility under the Affordable Care Act are rethinking those decisions. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Sarah Karlin-Smith of the Pink Sheet join KHN’s Julie Rovner to discuss these topics and more. Also this week, Rovner interviews KHN’s Fred Clasen-Kelly, who reported and wrote the latest KHN-NPR “Bill of the Month” feature, about a mysterious mishap during minor surgery.

Dec. 1, 2022

Letters to the Editor

Readers and Tweeters Decry Medical Billing Errors, Price-Gouging, and Barriers to Benefits

KHN gives readers a chance to comment on a recent batch of stories.

Nov. 28, 2022

Schools, Sheriffs, and Syringes: State Plans Vary for Spending $26B in Opioid Settlement Funds

The cash represents an unprecedented opportunity to derail the opioid epidemic, but with countless groups advocating for their share of the pie, the impact could depend heavily on geography and politics.

By Aneri Pattani

Nov. 22, 2022

A photo shows the outside of Pfizer's New York headquarters.

Pfizer’s Covid Cash Powers a ‘Marketing Machine’ on the Hunt for New Supernovas

While sales of its covid vaccines are falling, Pfizer plans to triple the price of the shots and use its bonanza from government contracts to buy and develop new blockbusters.

By Arthur Allen

Nov. 8, 2022

A photograph of an orange prescription bottle from above. There is only one pill left in the bottle.

Defense Department Health Plan Cuts Its Pharmacy Network by Nearly 15,000 Outlets

Many of the pharmacies were small, independent operations that had decided not to participate next year because of the lowered reimbursement being offered. But they were surprised by an early dismissal, and some patients with specialized drug needs could face difficulties in the transition.

By Patricia Kime

Nov. 8, 2022

Letters to the Editor

Readers and Tweeters Take Positions on Sleep Apnea Treatment

KHN gives readers a chance to comment on a recent batch of stories.

Oct. 27, 2022

Bill Of The Month

$38,398 for a Single Shot of a Very Old Cancer Drug

Lupron, a drug patented half a century ago, treats advanced prostate cancer. It’s sold to physicians for $260 in the U.K. and administered at no charge. Why are U.S. hospitals — which may pay nearly as little for the drug — charging so much more to administer it?

By Arthur Allen

Oct. 26, 2022

Podcast

KHN’s ‘What the Health?’: Biden Hits the Road to Sell Democrats’ Record

With the midterm elections rapidly approaching, President Joe Biden has taken to the road to convince voters that he and congressional Democrats have delivered for them during two years in power. Among the health issues highlighted by the administration this week are pandemic preparedness and the availability of over-the-counter hearing aids. The president also promised to sign a bill codifying the abortion protections of Roe v. Wade if Democrats maintain control of the House and Senate — even though it’s a long shot that there will be enough votes for that. Sarah Karlin-Smith of the Pink Sheet, Sandhya Raman of CQ Roll Call, and Mary Agnes Carey of KHN join KHN’s Julie Rovner to discuss these topics and more. Plus, for extra credit, the panelists recommend their favorite health policy stories of the week they think you should read, too.

Oct. 20, 2022

An illustration shows 3D renderings of the Epstein-Barr virus.

As Links to MS Deepen, Researchers Accelerate Efforts to Develop an Epstein-Barr Vaccine

Recent leaps in medical research have lent urgency to the quest to develop a vaccine against Epstein-Barr, a ubiquitous virus that has been linked to a range of illnesses, from mononucleosis to multiple sclerosis and several cancers.

By Liz Szabo

Oct. 19, 2022

A photo shows a pharmaceutical manufacturer filling capsules with medicine.

Waistlines and Bottom Lines

New Generation of Weight Loss Medications Offer Promise — But at a Price

People now have at their disposal more medicines that are effective at reducing weight, but none can counter obesity alone. One big problem: Insurance coverage remains spotty, and the costly drugs may be needed long term.

By Julie Appleby

Oct. 13, 2022

Severe Sleep Apnea Diagnosis Panics Reporter Until He Finds a Simple, No-Cost Solution

An industry has grown up around sleep apnea, stirring concerns about overdiagnosis and overtreatment.

By Jay Hancock

Oct. 3, 2022

A photo shows a sign outside the FDA's headquarters.

Pharma-Funded FDA Gets Drugs Out Faster, But Some Work Only ‘Marginally’ and Most Are Pricey

Since pharmaceutical companies started funding their FDA drug applications 30 years ago, the agency’s reviews have gone much faster — perhaps too fast.

By Arthur Allen

Sept. 30, 2022

Podcast

KHN’s ‘What the Health?’: On Government Spending, Congress Decides Not to Decide

Congress has once again decided not to decide how to fund the federal government in time for the start of the fiscal year, racing toward a midnight Sept. 30 deadline to pass a stopgap bill that would keep the lights on for two more months. However, it does appear the FDA’s program that gets drugmakers to help fund some of the agency’s review staff will be renewed in time to stop pink slips from being sent. Alice Miranda Ollstein of Politico, Rachel Cohrs of Stat, and Victoria Knight of Axios join KHN’s Julie Rovner to discuss these topics and more. Also this week, Rovner interviews filmmaker Cynthia Lowen, whose new documentary, “Battleground,” explores how anti-abortion forces played the long game to overturn Roe v. Wade.

Sept. 29, 2022

Centene Agrees to Pay Massachusetts $14 Million Over Medicaid Prescription Claims

Massachusetts is the latest state to settle with St. Louis-based Centene Corp. over allegations that it overcharged Medicaid prescription drug programs.

By Andy Miller and Samantha Young

Sept. 29, 2022

��ýҕ�l

Trump 2.0

Public Health

Audio Reports

Special Reports

More Topics

Drugs